Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 (patentes nacionales, patentes europeas, informes tecnológicos de patentes y búsquedas retrospectivas) se encuentra cerrado desde el 19 de junio. La solicitud de ayudas para los Bonos 1, 2 y 4 permanecen abiertos.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
141
resultados
Última actualización
13/08/2025 [07:48:00]
Resumen de: WO2025163643A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Resumen de: AU2024213250A1
The present disclosure provides compositions and methods for using stool-derived, eukaryotic, nucleic acid biomarkers to diagnose disease, assess disease activity, monitor mucosal healing, and predict therapeutic response. The described biomarkers can be used by practitioners to better diagnose, manage, and treat inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD).
Resumen de: JP2024015204A
To provide peptides, compositions and methods for treating gastrointestinal disorders.SOLUTION: The invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein, using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.SELECTED DRAWING: None
Resumen de: AU2024213780A1
Disclosed herein are methods of immunoassay for detecting HNE-generated fragments of the α3 chain or α4 chain of type IV collagen in a patient sample, and the use thereof for detecting and/or monitoring inflammatory bowel disease (IBD) or a particular level of severity thereof in a patient. Also disclosed are monoclonal antibodies and assay kits for use in said methods of immunoassay.
Resumen de: US2025249050A1
The invention relates to core components from five strains of independently isolated, identified and patent-deposited probiotics and fermentation metabolites thereof (postbiotics), as well as their use as a protector in alleviating dextran sulfate sodium (DSS) induced-colitis in mice. Further disclosed the mechanism of the probiotics and fermentation metabolites thereof (postbiotics) to alleviate colitis in mice.
Resumen de: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Resumen de: WO2025160484A1
Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.
Resumen de: US2025243548A1
Described herein are methods and compositions related to the discovery of associations in TNFSF15 15 and DcR3 genetic loci across in Caucasian, Puerto Rican, and Korean Crohn's Disease, as demonstrated via trans-ethnic fine mapping. The present invention provides methods of quantifying risk and diagnosing susceptibility to Crohn's disease in a subject by determining the presence of one or more risk variants are at the TNFSF15 (or TL1A) and/or DcR3 genetic loci.
Resumen de: US2025243546A1
The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.
Resumen de: US2025244340A1
The present disclosure contemplates detecting and treating a pathological condition, such as intestinal ischemia such as acute mesenteric ischemia, necrotizing enterocolitis, inflammatory bowel disease, and bowel graft rejection in a subject's intestinal tract. The methodology comprises obtaining a sample from the subject; detecting whether an analyte such as Villin-1, α-glutathione S-transferase, or intestinal fatty acid binding protein (I-FABP) is present in the sample by contacting the sample with an anti-analyte antibody and detecting binding between analyte and the antibody; and diagnosing the subject with the condition when, for example, the presence of analyte in the sample is detected and exceeds the level of analyte in a healthy control sample. A superparamagnetic bead includes an anti-Villin-1 antibody; an anti-α-glutathione S-transferase antibody, or an anti-intestinal-fatty acid binding protein (I-FABP) antibody. A superparamagnetic bead comprising a surface coating that binds Villin-1, α-glutathione S-transferase, or intestinal-fatty acid binding protein (I-FABP).
Resumen de: US2025244312A1
Some embodiments described herein relate to a method of screening candidate therapeutics for gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease, using an ex vivo biopsy high throughput platform. Some embodiments relate to a high-throughput method of screening an ex vivo biopsy for chromatin modifications associated with an gastrointestinal disease. Some embodiments relate to a multi-omic method of screening candidate therapeutics for treatment of gastrointestinal diseases, including inflammatory bowel diseases, ulcerative colitis, and Crohn's Disease.
Resumen de: US2022002805A1
Biomarkers that are indicative of the response to the therapy of the inflammatory bowel disease, including ulcerative colitis (UC) and Crohn's disease (CD), are described. Also described are probes capable of detecting the biomarkers and related methods and kits for predicting the response to the therapy of the inflammatory bowel disease.
Resumen de: CN116514983A
The invention relates to the technical field of biological pharmacy, in particular to a DR3 extracellular domain targeting nano antibody and application thereof. The method comprises the following steps: immunizing alpaca by using a DR3 extracellular domain of an insect expression system, separating peripheral blood lymphocytes, carrying out total RNA extraction, carrying out reverse transcription, amplifying a nano antibody sequence, and finally separating to obtain three nano antibodies which are respectively named A2, A6 and H10. The three nano antibodies have different antigen complementarity determining regions, SPR results show that the three nano antibodies all show high-affinity binding with human DR3 extracellular domains, and the nano antibodies provided by the invention are expected to provide experimental factual basis for treatment thinking of DR3-related diseases.
Resumen de: US2025237648A1
Embodiments of the disclosure relate to methods, compositions, and symptoms for detecting the imminent onset of a symptom of a gut inflammation medical condition and/or treatment thereof. The disclosure concerns microbial biosensors that detect a marker in the gut that is predictive of onset of at least one symptom of gut inflammation, such as with inflammatory bowel disease (IBD), for example, and such a sensor may include a promoter sensitive to the marker that is linked to expression of a detectable readout, such as in the feces of the individual. In various embodiments, the sensor includes a mechanism by which the biosensor is permanently activated to sense inflammation for future detection in the stool.
Resumen de: US2025237665A1
A targeted DEFA5 antibody is disclosed herein. The targeted DEFA5 antibody has a high degree of specificity with DEFA5 protein, particularly with peptide sequences of the P, B, and/or M binding sites of the DEFA5 protein. The targeted DEFA5 antibody may be incorporated into an assay for diagnosing and treating ulcerative colitis and Crohn's disease in a subject suffering from inflammatory bowel disease. The assay may be provided in a kit. The targeted DEFA5 antibody may be used in a method for measuring the level of DEFA5 or DEFA5 expression in a sample collected from a subject, and determining, based on the level of DEFA5 or DEFA5 expression, whether the subject is suffering from ulcerative colitis or Crohn's disease. A treatment may be based on the determination of whether the subject has ulcerative colitis or Crohn's disease.
Resumen de: WO2025155794A1
The present inventive concept provides a subject's fecal protein bioprofile and methods for establishing the same. Also provided are methods of determining a subject's risk for developing an inflammatory disorder, a neurological disorder, a neurodegenerative disorder, or a disorder associated with aging or monitoring the same. The inventive concept further provides kits for use in the methods described herein.
Resumen de: WO2025152918A1
Provided in the present invention are humanized anti-human CD132 monoclonal antibodies and the use thereof. The present invention performs humanized transformation on the basis of monoclonal chimeras 2D4 and 5H10, so as to obtain high-affinity humanized monoclonal antibodies h2D4H4K12 and h5H10H6K4 targeting the human CD132 by means of screening; therefore, without attenuating the antibody activity, the immunogenicity of parental chimeras is reduced, thus reducing the possible risk that medicated patients may generate immune responses on the antibodies. The monoclonal antibodies can be used for prevention, neutralization or treatment of autoimmune diseases related to IL-4, IL-7, IL-9, IL-15 and/or IL-21 cytokines, e.g. systemic lupus erythematosus, rheumatoid arthritis, vitiligo, psoriasis, alopecia areata, inflammatory bowel disease, systemic sclerosis, graft-versus-host disease and aplastic anemia.
Resumen de: WO2025155566A1
An MIS beveled driver and methods are provided for implanting beveled IBS bone compression and fully threaded screws to encourage bone fusion. The driver includes an elongated driver shaft extending from a shaped distal end to a proximal handle, a beveled sleeve having an angled distal-most surface adjacent to the shaped distal end that couples with the bone screw, and beveled marks on the driver shaft to indicate an orientation of the sleeve. The sleeve is affixed to the driver shaft such that the angle of the distal-most surface remains aligned with the beveled marks. The sleeve ensures that the bone screw only assembles with the driver in an orientation that enables aligning a proximal head portion of the bone screw to be flush with the surrounding bone surface. The sleeve includes a radio marker to enable observation of the bone screw by way of fluoroscopy.
Resumen de: CN119546632A
The present invention relates to a sandwich immunoassay for determining cross-linked collagen type V in a biological sample, and its use in identifying patients suffering from conditions associated with fibrosis, such as ankylosing spondylitis, inflammatory bowel disease, psoriasis and atopic dermatitis. The invention also relates to a kit for performing a sandwich immunoassay.
Resumen de: US2025230505A1
Disclosed herein are methods, kits and compositions for treating an inflammatory disease. These methods, kits and compositions may be particularly useful for subjects carrying a risk genotype and/or expressing a transcriptomic risk signature that is indicative of severe inflammatory disease phenotypes for which existing treatment options are limited.
Resumen de: US2025223626A1
The present invention describes methods of detecting IBS-D. Further described are methods selecting a therapy and methods of treatment for IBS-D. These methods are based, at least in part, on a subject's level of Desulfovibrio, Fusobacterium, or hydrogen sulfide.
Resumen de: EP4582099A2
Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Chain swapping between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present following administration of natalizumab, and thus to lower the activity of natalizumab in the patient. Differences in IgG4 levels across patients or within a single patient across time may change the pharmacokinetic profile of natalizumab. Patients with lower levels of IgG4 may experience higher nadir levels of natalizumab during a dosing period. Monitoring IgG4 and/or bivalent natalizumab levels, and determining a dose or dosage period based on the monitoring may improve the safety and/or efficacy of natalizumab therapy.
Resumen de: AU2023276693A1
The present disclosure relates, inter alia, to methods of treating ulcerative colitis with therapeutic intestinal alkaline phosphatases.
Resumen de: US2025213709A1
The present invention relates to a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells, for use in a method for the treatment of an inflammatory disease. The invention also relates to a method for treating an inflammatory disease by administering a conjugate that specifically targets a calcineurin inhibitor to T cells, such as Th17 cells. In addition, the invention relates to a method for identifying a subject likely to be resistant to steroid treatment, as well as a subject likely to benefit from treatment with a calcineurin inhibitor.
Nº publicación: WO2025141157A1 03/07/2025
Solicitante:
HAHN SCHICKARD GES FUER ANGEWANDTE FORSCHUNG E V [DE]
HAHN-SCHICKARD-GESELLSCHAFT F\u00DCR ANGEWANDTE FORSCHUNG E. V
Resumen de: WO2025141157A1
The invention relates to a method for assisting the diagnosis of a bowel disease comprising the steps of: a) providing an audio-recording of sounds emitted by the bowel of a subject for the duration of at least one classification time window, b) analyzing the processed audio data thereby classifying at least a fraction of the recorded sounds as bowel sound, c) computing at least one Mel Frequency Cepstral Coefficient (MFCC)-feature from at least a fraction of the recorded bowel sounds extracted in b), d) determining at least one statistical parameter, preferably the mean and/or variance, of at least a fraction of the Mel Frequency Cepstral Coefficient (MFCC)-features computed in c) within at least one classification time window, e) using an artificial intelligence (AI) to classify the at least one classification time window as either being indicative for the individual suffering from a bowel disease or for a healthy individual, wherein the AI is taking into account the in step d) determined at least one statistical parameter of at least a fraction of the MFCC- features, thereby predicting the likelihood of a bowel disease for the subject. The invention further relates to the use of the present method for the diagnosis of a bowel disease, to a computer-implemented method and a software or computer program for predicting the likelihood of a bowel disease in a subject.
BOPI
Sede Electrónica
